GSTHG-141 is under clinical development by Fujian Cosunter Pharmaceutical and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GSTHG-141’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GSTHG-141 overview

GSTHG-141 is under development for the treatment of hepatitis B. It is administered by oral route as a tablet. It is a carboxylic acid derivative.

Fujian Cosunter Pharmaceutical overview

Fujian Cosunter Pharmaceutical (Cosunter) is a pharmaceutical company. It operates in the business of research, development, manufacture and sales of nucleoside anti-HBV drugs. The company offers entecavir capsules, adfovir dipivoxil tablets, and tenofovir disoproxil fumarate capsules. Cosunter offers crude drugs and solid preparations in the form of tablets, capsules, granules, medicinal teas and others for use in the treatment of hepatitis B virus, liver fibrosis, and liver cancer. Its tenofovir disoproxil fumarate is an inhibitor of nucleotide reverse transcriptase for the treatment of chronic hepatitis b. Cosunter is headquartered in Fuzhou City, Fujian, China.

For a complete picture of GSTHG-141’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.